The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

OBJECTIVE: The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEA...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Meneghini, Luigi, Atkin, Stephen L., Gough, Stephen C.L., Raz, Itamar, Blonde, Lawrence, Shestakova, Marina, Bain, Stephen, Johansen, Thue, Begtrup, Kamilla, Birkeland, Kåre I.
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2013
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3609505/
https://ncbi.nlm.nih.gov/pubmed/23340894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-1668
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items